CLLS — Cellectis S.A.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1627281 ·
France
Last close
$3.19
Market Cap
$231.92M
52W High
$3.76
52W Low
$2.35
ADV30
17,753
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,229,000 | 2,874,000 | -23,520,000 | -21,819,000 | 267,365,000 | 35,590,000 | 226,298,000 |
| Mar 2026 | 5,777,000 | 3,457,000 | -25,168,000 | -17,765,000 | 289,187,000 | 34,841,000 | 229,267,000 |
| Dec 2025 | 10,396,000 | 7,397,000 | -17,351,000 | -26,318,000 | 324,720,000 | 61,533,000 | 248,819,000 |
| Sep 2025 | 35,172,000 | 32,815,000 | 8,041,000 | 589,000 | 343,045,000 | 52,243,000 | 242,567,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,654,000
Investing CF
$-39,871,000
Financing CF
$-17,570,000
CapEx
$-3,403,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.61
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-351,939,000
Inventory
—
Receivables
$15,050,000
ST Investments
$150,822,000
EBIT TTM
$-59,484,000
Pretax Income TTM
$-67,608,000
Interest Exp TTM
$8,124,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$63,823,000
EBITDA
$-46,677,000
Free Cash Flow
$107,701,376
Enterprise Value
$161,201,232
Total Cash
$166,686,000
Total Debt
$80,350,000
Shares Out
72,701,207
Trailing EPS
$-0.64
Book Value
$0.56
ROE
-94.5%
ROA
-11.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,949,000 | -33,076,000 | -67,593,000 | 324,720,000 | 248,819,000 | — | -39,401,000 |
| Dec 2024 | 41,506,000 | -59,554,000 | -36,761,000 | 383,544,000 | 252,511,000 | — | 22,989,000 |
| Dec 2023 | 755,000 | -97,303,000 | -101,059,000 | 334,270,000 | 249,575,000 | — | -24,746,000 |
| Dec 2022 | 19,171,000 | -89,666,000 | -106,139,000 | 261,216,000 | 135,275,000 | — | -87,444,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.62
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.19 · call volume: 67 · put volume: 0
Expected Move to 2027-02-19:
±$2.57
(80.56%) —
implied range
$0.62 –
$5.76
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DTIL | PRECISION BIOSCIENCES INC | $233.23M | $8.45 | — |
| TARA | Protara Therapeutics, Inc. | $228.70M | $3.87 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $222.38M | $3.08 | — |
| CGEN | COMPUGEN LTD | $245.34M | $2.59 | — |
| IPHA | Innate Pharma SA | $246.30M | $2.20 | — |
News headlines (Yahoo Finance, 1h cache)
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
2026-08-21 15:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
2026-08-14 15:08 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading
2026-08-24 15:15 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
2026-08-20 15:17 · Yahoo
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
2026-08-18 15:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
2026-08-17 15:12 · Yahoo
European Equities Traded in the US Rise in Thursday Trading
2026-08-13 15:14 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
2026-08-11 15:26 · Yahoo
Cellectis Reports Financial Results for the Second Quarter 2026
2026-08-06 20:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading
2026-08-06 15:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.